Jasper Therapeutics, Inc. Logo

Jasper Therapeutics, Inc.

Develops mast cell-depleting antibody therapies for chronic diseases and stem cell transplants.

JSPR | NDAQ

Overview

Corporate Details

ISIN(s):
US4718712023 (+3 more)
LEI:
Country:
United States of America
Address:
2200 BRIDGE PKWY SUITE #102, 94065 REDWOOD CITY
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Jasper Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for mast cell-driven diseases and as a conditioning agent for hematopoietic stem cell transplantation. The company's lead product candidate is briquilimab, a targeted anti-KIT (CD117) monoclonal antibody designed to deplete mast cells. Jasper is evaluating briquilimab in clinical studies for the treatment of chronic immunological and inflammatory diseases, including chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU), and allergic asthma. The company's mission is to develop safer and more effective therapies for patients with serious chronic diseases by harnessing the power of mast cell depletion.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Jasper Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Jasper Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Jasper Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
CORESTEMCHEMON Inc. Logo
Develops stem cell therapies & provides preclinical CRO services to pharma & biotech.
South Korea 166480
Corline Biomedical AB Logo
Develops heparin-based coatings for medical device biocompatibility and regenerative medicine.
Sweden CLBIO
CorMedix Inc. Logo
Develops a catheter lock solution to prevent bloodstream infections in hemodialysis patients.
United States of America CRMD
Cosma Spolka Akcyjna Logo
Produces natural hemp supplements and pharmaceutical raw materials for retail & wholesale markets.
Poland COS
COSMO Pharmaceuticals N.V. Logo
Specialty pharma for gastroenterology/dermatology, offering colon treatments & manufacturing services.
Netherlands COPN
Cosmos Health Inc. Logo
A global healthcare firm developing & distributing nutraceuticals, generics, and OTC medications.
United States of America COSM
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. Logo
Biotech firm developing cell therapies for regenerative medicine and immunotherapy applications.
United States of America CELZ
CRESCENT BIOPHARMA, INC. Logo
A biotech company developing bispecific antibody therapies to treat solid tumors.
United States of America CBIO
Crinetics Pharmaceuticals, Inc. Logo
Develops novel therapeutics for rare endocrine diseases and related tumors.
United States of America CRNX
CRISPR Therapeutics AG Logo
Develops transformative CRISPR gene-based medicines for diseases like sickle cell.
United States of America CRSP

Talk to a Data Expert

Have a question? We'll get back to you promptly.